Bayer/Onyx Pharmaceuticals: Nexavar approval in liver cancer will boost sales (Pharmaceutical Business Review)
Bayer and Onyx Pharmaceuticals Nexavar has received yet more positive regulatory news, winning approval in the US for the treatment of hepatocellular carcinoma. The targeted therapy can now expect to be adopted as the standard first-line treatment. Coupled with the recent approval in the EU for the same indication, overall sales of the drug are likely to be substantially boosted.

Health Canada Licenses QIAGEN's New Molecular Test For Hepatitis B (Medical News Today)
QIAGEN announced that its newly released hepatitis B virus (HBV) assay kit is in compliance with Health Canada's medical device requirements. The artus HBV LC PCR Kit, which monitors the viral load of HBV infected patients, is now available to doctors in Canada to help them determine the success of a treatment. [click link for full article]

Increased Regulations Slow Approvals in Wall Street Transcript Specialty Pharmaceuticals Report (Wall Street Transcript via Yahoo! Finance)
67 WALL STREET, New York-November 19, 2007-The Wall Street Transcript has just published its Specialty Pharmaceuticals issue, a report offering a timely review of the sector to serious investors and industry executives. This 26-page feature contains industry commentary through in-depth interviews with 4 analysts and top management from 1 firm. The full issue is available by calling (212) ...